Conference Coverage

Inhibitor appears to strengthen anti-BCMA CAR T cells in myeloma patients


 

REPORTING FROM ASH 2019

– A gamma secretase inhibitor could enhance the efficacy of B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cells in patients with relapsed or refractory multiple myeloma, a phase 1 trial suggests.

Dr. Andrew J. Cowan, University of Washington and Fred Hutchinson Cancer Research Center in Seattle Jennifer Smith/MDedge News

Dr. Andrew J. Cowan

The inhibitor, JSMD194, increased BCMA expression in all 10 patients studied. All patients responded to anti-BCMA CAR T-cell therapy, including three patients who had previously failed BCMA-directed therapy.


Nine patients remain alive and in response at a median follow-up of 20 weeks, with two patients being followed for more than a year. One patient experienced dose-limiting toxicity and died, which prompted a change to the study’s eligibility criteria.

Andrew J. Cowan, MD, of the University of Washington and Fred Hutchinson Cancer Research Center in Seattle, presented these results at the annual meeting of the American Society of Hematology.

Next Article: